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tone	 deacetylase	 inhibitors	 have	 shown	 promising	 activity	 against	 CSCs.	
Combining	 epigenetic	 drugs	 such	 as	 lysine-	specific	 histone	 demethylase-	1A	 in-
hibitors	or	histone	deacetylase	inhibitors	with	PARPi/anti-	PD-	1/PD-	L1	is	a	novel,	
potentially	 synergistic	 strategy	 for	 priming	 tumors	 and	 overcoming	 resistance.	
Furthermore,	such	an	approach	could	pave	the	way	for	the	identification	of	new	
upstream	epigenetic	and	genetic	signatures.
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1  | BACKGROUND





to	 standard	cytotoxic	 chemotherapy	 regimens,	 recurrence	 is	 com-
mon,	and	retreatment	with	 further	 lines	of	chemotherapy	remains	








death	 and	 depletes	 the	 metastasis-	driving	 cancer	 stem	 cell	 (CSC)	
population	through	epigenetic	modulation.
Immune	 checkpoint	 inhibition	 and	 immune-	mediated	 cytotox-
icity	 have	 shown	 impressive	 durable	 activity	 in	many	 hematologi-
cal	 and	 solid	 organ	 cancers	 with	 an	 acceptable	 toxicity	 profile.2 
Although	a	 large	proportion	of	TNBCs	express	high	 levels	of	pro-
grammed	cell	death-	ligand	1	 (PD-	L1),	have	a	high	mutational	 load,	
and	 are	 associated	 with	 high	 numbers	 of	 CD8+	 tumor-	infiltrating	




novel	drugs	 that	cause	cell	 cycle	arrest	and	cell	death	by	 interfer-
ing	with	DNA	 repair.4	 Several	PARPi	have	been	 tested	 in	patients	
with	various	cancers	including	ovarian,	breast,	and	prostate	cancers.	
Impressive	 responses	 have	mainly	 been	 seen	 in	 early	 phase	 trials	
and	some	phase	III	trials,	especially	in	BRCA-	mutant	ovarian	cancer	





resistance	 develops	 in	most	 patients	with	 no	 significant	 improve-
ment	in	overall	survival	(OS).5,6




ity	 is	 triggered	by	binding	of	PARP1	to	single-	strand	breaks	 through	
the	 two	zinc	 fingers	 at	 the	N-	terminal	42	kDa	DNA-	binding	domain,	
which	leads	to	enzymatic	activation.7	Using	NAD	as	a	substrate,	PARP1	
catalyzes	 the	 transfer	of	 polymer	of	ADP	 ribose	 (PAR)	molecules	 to	











Synthetic	 lethality	 is	 a	 concept	 in	 which	 defects	 in	 one	 or	 two	
genes/repair	mechanisms	have	minimal	effects	on	 the	cell,	whereas	






PD- L1 level Phase
No. of 
patients ORR% Comments
Loi	et	al68 2017 Pembrolizumab Trastuzumab ER+/−/PD-	L1+/− Ib/II 58 15 ORR	39%	in	
PD-	L1+,	TILs	
>5%
Rugo	et	al69 2016 Pembrolizumab Single	agent ER+HER2−/>1% Ib 25 12
Nanda	et	al70 2016 Pembrolizumab Single	agent TNBC/>1% Ib 27 18
Schmid	et	al71 2017 Atezolizumab Single	agent TNBC/>5% I 115 10 17%	ORR	in	
PD-	L1+
Adams	et	al72 2016 Atezolizumab Atezolizumab/
abraxane
TNBC,	PD-	L1+/− Ib 32 42





2017 Durvalumab Tremelimumab NR I 18 17 43%	in	TNBC
ER,	estrogen	receptor;	HER2,	human	epidermal	growth	factor	receptor	2;	NR,	not	reported;	ORR,	objective	response	rate;	PD-	L1,	programmed	cell	
death	ligand-	1;	TIL,	tumor	infiltrating	lymphocyte;	TNBC,	triple-	negative	breast	cancer.
     |  3385PRASANNA et Al.
Farmer	et	al10	reported	that	homologous	recombination	(HR)-	deficient	
BRCA1/2-	mutated	 human	 cell	 lines	 and	 mouse	 models	 were	 much	
more	sensitive	to	PARPi	compared	to	BRCA	WT	cells.	Although	this	
synthetic	lethality	was	initially	thought	to	be	due	to	reliance	of	BRCA-	
mutant	 cells	on	 the	 single-	strand	break	 repair	 (base	excision	 repair)	
pathway	for	survival,	emerging	reports	suggests	that	PARP	trapping	





3  | POLY (ADP-  RIBOSE) POLYMER A SE 
INHIBITORS IN BRE A ST C ANCER
Triple-	negative	breast	cancers	comprise	15%-	20%	of	breast	cancers	
overall	 and	 70%	 of	 BRCA1	 and	 20%	 of	 BRCA2	 mutation	 carriers,	
































4  | RESISTANCE TO PARPI
Poly	 (ADP-	ribose)	 polymerase	 inhibitor-	treated	 cells	 acquire	 resist-
ance	 either	 directly	 or	 indirectly	 related	 to	 restoration	of	HR	 repair	
or	through	other	mechanisms.	These	can	be	broadly	categorized	into	

















combinations Phase No. of patients ORR% PFS (mo) OS (HR/P) OS (mo)
Litton	et	al13 2017 Talazoparib Single	agent	vs	
chemo









2015 Olaparib Single	agent II 62 13 3.7 NA 11
Turner	et	al6 2017 Talazoparib Single	agent II 84 28 4 NA NR
Han	et	al76 2018 Veliparib V+Cb+P,	
Pl+Cb+P	(&	
V+Tem)
II 284 78	vs	61 14 vs 12 (0.75/0.1) 28	vs	26
Cb,	carboplatin;	chemo,	chemotherapy;	HR/P,	hazard	ratio/P	value;	NA,	not	applicable;	NR,	not	reported;	ORR,	overall	response	rate;	OS,	overall	sur-
vival;	P,	paclitaxel;	PFS,	progression-	free	survival;	Pl,	placebo;	Tem,	temozolomide;	V,	veliparib.











PARP1	 on	 DNA.	 Cytotoxicity	 was	 greater	 with	 olaparib/temozo-












that	defects	 in	other	DNA	repair	genes	commonly	 found	 in	human	




CTIP,	BRCA1,	 and	RAD51	 transcription.25,26	Deficiencies	 in	 several	
other	pathways	could	also	 increase	PARPi	 sensitivity,	 and	drugs	 in-
hibiting	the	mTOR/PI3K	pathway,	heat	shock	protein	90	(HSP90),	and	
histone	deacetylase	inhibitors	(HDACi)	are	currently	undergoing	trials.
6  | NOVEL THEORIES OF PARPI 
RESISTANCE
6.1 | Programmed cell death- ligand 1 theory
Cancer	 cells	 can	 be	 recognized	 and	 eliminated	 by	 the	 innate	 and	
adaptive	 immune	 systems,	 especially	 in	 the	 early	 course	of	 tumor	
development.	 T	 cell	 recognition	 of	 cancer	 antigens	 and	 activation	
are	crucial	 to	 immunogenic	cancer	cell	death,	which	 is	 initiated	by	
antigen	 presentation	 by	 antigen-	presenting	 cells.	 Tumor	 antigens	
are	 presented	 through	 the	MHC	 to	T-	cell	 receptors,	 facilitated	by	
co-	stimulatory	molecules	like	B7	and	CD28	to	fully	activate	T	cells.	
Various	 other	 co-	stimulatory	 and	 co-	inhibitory	 checkpoint	 mol-





The	 combination	 of	 PARPi	 and	 immunotherapy	 is	 one	 novel	 ap-
proach	currently	being	investigated	(Table	S1).28,29	Several	arguments	
have	 been	 proposed	 to	 rationalize	 such	 combinations.	 First,	 PARPi-	
related	cytotoxicity	could	release	damaged	DNA,	which	represents	a	













































meobox	 A9;	 HR,	 homologous	 recombinant;	 NF-	κB,	 nuclear	 factor-	κB;	
SLFN11,	Schlafen	family	member	11.
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SUM159	with	olaparib	and	talazoparib	as	the	PARP1i,	whereas	the	
latter	 used	 the	 BR5-	Akt/BRCA1	 deficient	 and	 T22/BRCA1	 profi-
cient	ovarian	cancer	cell	lines	and	veliparib.











tions	 such	as	 inflammation	and	 low	nutrient	availability,	metabolic	
reprogramming,	 marked	 resistance	 to	 oxidative	 stress,	 the	 ability	
to	 rapidly	 activate	 detoxifying	 strategies	 by	 ATP-	binding	 cassette	
transporters,	enhanced	and	quick	DNA	damage	responses,	and	im-
paired	apoptotic	machinery.35
6.2.1 | Epithelial- mesenchymal transition 
(EMT) and CSCs
Epithelial-	mesenchymal	 transition	 is	 a	 latent	 embryonic	 program	
implicated	 in	 cancer	 invasion	 and	 metastasis.36	 In	 EMT,	 epithelial	
cancer	cells	lose	their	adhesive	properties	and	acquire	a	mesenchy-
mal	 trait.	 Epithelial-	mesenchymal	 transition	 is	 a	 complex	 process	
that	 involves	many	 transcription	 factors	 including,	 but	 not	 limited	
to,	 SNAIL,	 SLUG,	 TWIST,	 ZEB1,	 SIP1,	 and	 E47.	 Many	 pathways	
play	 crucial	 roles	 in	 EMT	 such	 as	Wnt,	 Notch,	 nuclear	 factor-	κB,	
Hedgehog,	and	transforming	growth	factor-	β	(TGF-	β).37	Cells	under-
going	 EMT	 can	 acquire	 stem	 cell-	like	 features	 to	 become	CSCs.38 






6.2.2 | Effect of PARPi on CSCs
The	 role	of	PARPi	on	CSCs	 is	unknown;	however,	 there	 is	 indirect	
evidence	to	suggest	CSCs	are	resistant	to	PARPi.	Yamaguchi	et	al39 
reported	that	inhibition	of	PARP1	with	olaparib	activated	EZH2	and	
increased	 the	 formation	 of	 breast	 cancer	 CSCs.	 In	 another	 study	




these	mechanisms,	and	 it	 is	 reasonable	 to	presume	that	PARPi	are	
very	unlikely	to	exert	significant	cytotoxicity	on	CSCs	(Figure 1).





of	 responders	 and	non-	responders	 in	 pretreatment	 tumor	 speci-
mens	 of	metastatic	melanomas	 from	patients	 treated	with	PD1i.	
Resistant	signatures	in	nonresponders	included	genes	involved	in	
angiogenesis,	 immunosuppression,	 monocyte/macrophage	 che-
motaxis,	and	EMT.	Gene	ontology	enrichment	and	gene	set	variant	
analysis	also	confirmed	that	these	tumor	specimens	were	enriched	
in	 EMT	 and	TGF-	β	 pathway	 genes,	 both	 of	which	 are	 implicated	
in	CSC	development.	In	addition,	Wu	et	al42	reported	high	PD-	L1	
levels	in	breast	and	colon	CSCs	compared	to	non-	CSCs.	Expression	
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correlation	between	the	stemness	score	of	the	breast	cancer	and	
PD-	L1	 levels.43	 Furthermore,	 PD-	L1	 knockdown	 decreased	 ex-
pression	of	embryonic	stem	cell	transcription	factors	like	octamer-	




Epigenetics	 is	 defined	 as	 heritable	 modifications	 to	 DNA	 without	
alteration	in	the	nucleotide	sequence,	resulting	in	altered	gene	tran-
scription	and	chromatin	structure.45	Epigenetic	changes	include	DNA	






7.1 | Lysine- specific histone demethylase- 1A 
(LSD1) and LSD1 inhibitors










levels	 are	 seen	during	EMT	 in	MCF-	7	breast	 cancer	 cells	 following	
stimulation	with	Phorbol	12-	myristate-	13-	acetate/TGF-	β	and	in	fully	













7.2 | Histone deacetylase and HDACi
Histone	 deacetylase	 is	 a	 family	 of	 hydrolases	 that	 remove	 acetyl	
groups	 from	 lysine	 residues	 on	 histones,	 and	 they	 play	 important	
and	varied	roles	in	tumorigenesis,	including	regulation	of	numerous	
genes	 responsible	 for	 tumor	 initiation	 and	 progression,	 angiogen-
esis,	 and	 cell	migration.50	 Therefore,	HDACi	 have	 emerged	 as	 po-
tential	anticancer	drugs	that	inhibit	DNA	repair.	In	addition,	HDACi	












7.3 | Do epigenetic drugs synergize with PARPi and 
PD1i?
7.3.1 | Epigenetic drugs and PARPi








to	 be	 related	 to	 downregulation	 of	 the	 transcription	 factor	 E2F1.	
Further	 supporting	 this,	 PCI-	24781,	 an	HDACi,	 decreased	 RAD51	
and	HR	pathway	expression.55	In	this	background,	many	epigenetic	


















fold	 increase	 in	CSCs	 in	BRCA-	mutant	SUM149	and	HCC-	1937	cells	
without	changes	in	absolute	CSC	numbers.	Addition	of	vorinostat,	a	
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pan-	HDAC	inhibitor,	reduced	the	absolute	number	of	CSCs	in	SUM149,	
SUM159,	 and	HCC1397	 cultures	 and	 sensitized	 the	 TNBC	CSCs	 to	
PARPi	 irrespective	of	 the	BRCA	 status.	 The	 researchers	 also	 found	
reduced	 formation	of	RAD51	foci	at	 sites	of	DNA	damage	with	 the	
addition	of	vorinostat,	hence	creating	a	BRCAness	phenotype.40
7.3.2 | Epigenetics and immunotherapy
Epigenetic	drugs	 could	potentiate	 the	 antitumor	 activity	of	 immuno-
therapy	by	either	reducing	F	Forkhead	box	P3+	regulatory	T	cells,	re-












8  | FINAL DISCUSSION AND FUTURE 
STR ATEGIES
The	combination	of	PARPi	with	a	PD-	1	or	PD-	L1	inhibitor	has	a	very	
promising	 biological	 rationale	 for	 synergy;	 however,	 as	 discussed	
above,	both	drugs	are	unlikely	to	have	a	significant	impact	on	CSCs.	
This	 could	 lead	 to	 residual	 tumors	 enriched	with	CSCs	 that	might	




















We,	 therefore,	 believe	 that	 combination	 strategies	 targeting	
multiple	 signals	 in	 the	 same	 cascade	 are	 less	 likely	 to	 provide	 an	
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